Overlooked Opportunities: Three Best Stocks Under $100 for Long-Term Growth

Finding quality growth stocks with accessible price points has become increasingly challenging in today’s market. Yet savvy investors who look beyond mainstream picks can discover compelling opportunities priced under $100 per share. These affordable entry points aren’t just about lower costs—they enable portfolio diversification, allowing you to build exposure to promising companies across different sectors while they’re still establishing their market positions. Of course, such opportunities often come with greater price volatility and execution risk. For those seeking best stocks under $100 right now, three compelling candidates worth investigating are CRISPR Therapeutics (NASDAQ: CRSP), Celsius (NASDAQ: CELH), and KB Home (NYSE: KBH).

CRISPR Therapeutics: Gene Therapy Innovation at Affordable Valuation

CRISPR Therapeutics represents a fascinating entry point into the gene-editing space for long-term investors. This biotech company has faced considerable headwinds in recent years, yet a significant catalyst has emerged: regulatory approval of Casgevy, its groundbreaking cell therapy co-developed with Vertex Pharmaceuticals. This treatment targets rare blood disorders including sickle cell disease and beta-thalassemia—conditions affecting thousands of patients worldwide.

What makes Casgevy particularly noteworthy is its pricing structure. At over $2 million per patient, the therapy commands premium economics that could substantially reshape CRISPR’s financial trajectory. Under the partnership structure, CRISPR captures 40% of revenues while Vertex retains the remainder—a profit split that could generate meaningful returns as patient adoption accelerates.

The company’s current financial profile shows no consistent revenue streams and ongoing losses, but management has demonstrated disciplined cost control, preventing expenses from spiraling. This contrasts favorably with many early-stage biotech competitors that lack approved products. As Casgevy rollout progresses, market participants should expect CRISPR’s financial metrics to inflect positively. While not devoid of risk, the risk-reward proposition at current valuations appears asymmetrically favorable compared to similarly-staged biotech enterprises.

Celsius: Beverage Industry Growth Despite Near-Term Headwinds

Energy drink manufacturer Celsius presents an intriguing contrarian opportunity for patient investors. The company’s share price has contracted sharply in recent periods following disappointing growth guidance and inventory adjustments—a dynamic that has made entry points far more accessible for new investors.

The bullish case for Celsius rests on several structural advantages. Most notably, PepsiCo functions as both a distribution partner and investor, having committed $550 million to the company several years ago. This partnership represents more than financial backing; it signals PepsiCo’s confidence in the brand’s long-term potential and provides distribution reach that took most beverage startups years to build organically.

Current headwinds—specifically PepsiCo’s optimization of inventory levels for Celsius products—appear temporary in nature rather than symptomatic of fundamental business deterioration. The broader opportunity remains substantial given untapped geographic markets and demographic expansion potential. Notably, the company achieved operating profitability in three of its past four quarters, demonstrating that the underlying business model can generate positive cash flows despite near-term revenue deceleration. For investors comfortable with volatility, this combination of established distribution, strategic investor backing, and near-term margin challenges creates an asymmetric payoff scenario.

KB Home: Housing Sector Value Play in Favorable Rate Environment

KB Home represents the most traditionally-valued holding among these three, trading near the lower end of the sub-$100 range. The residential homebuilder has experienced meaningful momentum as macroeconomic conditions have shifted favorably, particularly with declining interest rate environments making home affordability more attractive to prospective buyers.

KB Home’s operational metrics support this thesis convincingly. Recent quarterly revenues approximated $1.8 billion and expanded double-digit percentages compared to the prior-year equivalent period. Management commentary highlighted strengthening demand trends, setting up the possibility for continued acceleration in subsequent quarters. Trading at approximately 11 times trailing earnings multiples, the company offers both growth characteristics and reasonable valuation—a rare combination in the housing sector.

Beyond near-term momentum, KB Home occupies a top-tier position within the U.S. homebuilding landscape. As interest rates potentially decline further, demand tailwinds could extend, providing sustained tailwinds for residential construction volumes and pricing power.

Constructing a Diversified Growth Portfolio with Accessible Entry Points

These three best stocks under $100 showcase how investors can construct meaningful exposure to secular growth themes—medical innovation, consumer brands, and housing demand—without requiring substantial capital deployment per position. By concentrating on affordable growth stocks with distinct catalysts and competitive advantages, portfolio construction becomes more flexible while concentration risk diminishes.

The key insight remains that lower nominal prices don’t indicate lower quality or reduced growth potential. Rather, they represent tactical opportunities for investors willing to accept temporary price volatility in exchange for exposure to transformative business models. Each of these candidates presents a distinctly different risk-reward profile, enabling thoughtful portfolio construction aligned with individual risk tolerances and time horizons.